+63 927 949 5432



Sangkat Phsar Derm Tkov, Phnom Penh Street 484 12307 Cambodia
About reach52

Reach52 (formally Allied World Healthcare) radically transforms service delivery models for primary care services in rural and remote areas of LMICs using a digital public health approach. We partner with governments, multi-laterals and non-profits to make healthcare solutions go further into communities where access is low to non-existent. We are headquartered in Singapore, with active projects in both Cambodia and Philippines. In the 3 years since our inception, we have engaged more than 170,000 residents and 1,000 health care workers (HCWs) in dozens of partner-communities. Our solutions have won numerous awards across Asia, including Singtel Future Makers, Facebook’s Startup Station, Accenture Health Innovation Challenge (Asia), United Nations World Summit Award (Singapore), and DBS Foundation Social Enterprise Awardee. We have formal partnerships to implement access-oriented programs for major multinational pharmaceutical companies and distributers such as Novartis, Gilead, Sandoz, and Zuellig Pharma. Reach52 is currently in the planning phases of a project in Western Visayas, Philippines to provide health care worker training, as well as community screening, diagnostic, and treatment services for hepatitis B virus (HBV). This project is targeted at low-income residents in rural and remote areas who currently lack access to HBV services due to financial or geographic barriers. The guidelines adapted for this project are designed to be implemented in a low-resource setting, and include draft protocols recently developed by the hepatology society of Philippines. Screening and diagnosis will be conducted through a combination of rapid diagnostic tests and dried blood spot samples. Task shifting will be employed to provide improved access to treatment initiation and monitoring in community settings. Tenofovir will be made available at rates below current retail prices. The project will be implemented in cooperation of our network of peer workers and coordinated through use of our proprietary digital health platform. This initial phase of the project is designed to screen 10,000 residents for HBsAg seropositivity and will be expanded in the future based on results. The project is being run in cooperation with a broad range of local stakeholders, including rural health units, through financial support from Gilead Pharmaceutical.